In this network meta- analysis , we demonstrated that SeR did not show clinical ly meaningful improvement in LUTS and PF .
PATIENT SUMMARY In the present study , we found no clinical ly meaningful improvement of Serenoa repens for the treatment of lower urinary tract symptoms/benign prostatic enlargement .
CONTEXT International guidelines do not make any specific recommendations on Serenoa repens ( SeR ) for the treatment of male lower urinary tract symptoms ( LUTS ) secondary to benign prostatic enlargement ( BPE ) , due to product heterogeneity and method ological limitations of the published trials and meta-analyses .
OBJECTIVE We aim ed to compare the clinical efficacy of hexanic extract of SeR ( HESr ) versus non-HESr ( nHESr ) versus placebo versus alpha-blockers ( ABs ) in patients affected by LUTS secondary to BPE through a network meta- analysis method .
Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
OBJECTIVES To examine the efficacy and safety of tadalafil in Asian men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia . METHODS Asian men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia were r and omized to once-daily placebo ( n=154 ) , tadalafil 2.5 mg ( n=151 ) , tadalafil 5.0 mg ( n=155 ) or tamsulosin 0.2 mg ( active control , n=152 ) for 12 weeks . RESULTS Total International Prostate Symptom Score least-squares mean changes from baseline to end-point significantly improved with tadalafil 2.5 mg ( -4.8 , P=0.003 ) and 5 mg ( -4.7 , P=0.004 ) versus placebo ( -3.0 ) . Significant improvement in the International Prostate Symptom Score versus placebo was observed earlier ( week 2 ) for tadalafil 5.0 mg than for tadalafil 2.5 mg ( week 8) . Significant improvements ( P<0.05 ) in both tadalafil groups versus placebo were observed for the International Prostate Symptom Score voiding subscore , International Prostate Symptom Score Quality of Life , and for Patient and Clinician Global Impressions of Improvement . Significant improvements versus placebo were observed in the International Prostate Symptom Score storage subscore for tadalafil 5.0 mg ( -1.7 , P=0.021 ) , but not tadalafil 2.5 mg ( -1.5 , P=0.072 ) . No significant improvements in benign prostatic hyperplasia Impact Index or improvements in peak urinary flow rates were observed with tadalafil 2.5 mg or 5.0 mg versus placebo . Tamsulosin treatment result ed in significant improvements versus placebo across all efficacy parameters , except for peak urinary flow rates . Safety results were consistent with the known tadalafil and tamsulosin safety profiles . CONCLUSIONS Tadalafil once daily represents an effective and well tolerated medical treatment for Asian men presenting with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
In this network meta- analysis , we demonstrated that SeR did not show clinical ly meaningful improvement in LUTS and PF .
PATIENT SUMMARY In the present study , we found no clinical ly meaningful improvement of Serenoa repens for the treatment of lower urinary tract symptoms/benign prostatic enlargement .
CONTEXT International guidelines do not make any specific recommendations on Serenoa repens ( SeR ) for the treatment of male lower urinary tract symptoms ( LUTS ) secondary to benign prostatic enlargement ( BPE ) , due to product heterogeneity and method ological limitations of the published trials and meta-analyses .
OBJECTIVE We aim ed to compare the clinical efficacy of hexanic extract of SeR ( HESr ) versus non-HESr ( nHESr ) versus placebo versus alpha-blockers ( ABs ) in patients affected by LUTS secondary to BPE through a network meta- analysis method .